Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eurofins-CerepXPAR:ALECR 28 PB Ratio is 1.07 as of Aug. 25, 2026, which is 28% below its 10-year median of 1.49. GuruFocus rates XPAR:ALECR with a GF Score™ of 28/100 and a GF Value™ of €20,199.84. The stock has 4 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Eurofins-Cerep ranks better than 77.2% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-25), Eurofins-Cerep's share price is €16300.00. Eurofins-Cerep's Book Value per Share for the quarter that ended in Dec. 2025 was €15,296.60. Hence, Eurofins-Cerep's PB Ratio of today is 1.07.
Good Sign:
Eurofins-Cerep SA stock PB Ratio (=1.07) is close to 5-year low of 1.
The historical rank and industry rank for Eurofins-Cerep's PB Ratio or its related term are showing as below:
XPAR:ALECR'
s PB Ratio Range Over the Past 10 Years
Min: 0.78 Med: 1.49 Max: 2.65
Current: 1.07
During the past 13 years, Eurofins-Cerep's highest PB Ratio was 2.65. The lowest was 0.78. And the median was 1.49.
XPAR:ALECR's PB Ratio is ranked better than 77.2% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.15
vs XPAR:ALECR: 1.07
During the past 12 months, Eurofins-Cerep's average Book Value Per Share Growth Rate was 6.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 19.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Eurofins-Cerep was 24.50% per year. The lowest was -21.70% per year. And the median was 8.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Eurofins-Cerep PB Ratio Related Terms
Eurofins-Cerep PB Ratio Historical Data
* Premium members only.
The historical data trend for Eurofins-Cerep's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins-Cerep's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins-Cerep PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins-Cerep's PB Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins-Cerep's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Eurofins-Cerep's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Eurofins-Cerep (XPAR:ALECR) has a PB Ratio of 1.07 as of Aug. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Eurofins-Cerep and its competitors. This is 28% below median its historical median of 1.49. Over the past decade, Eurofins-Cerep's PB Ratio has ranged from 0.78 to 2.65. According to the industry distribution chart, Eurofins-Cerep ranks #44 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 22.8%.
Is Eurofins-Cerep's PB Ratio too high?
Eurofins-Cerep's current PB Ratio of 1.07 is 28% below median its 10-year median of 1.49. Over the past 10 years, this metric has ranged from a low of 0.78 to a high of 2.65. The Medical Diagnostics & Research industry median PB Ratio is 2.15. Eurofins-Cerep's value of 1.07 is 50.2% below this industry median. Based on the distribution chart, Eurofins-Cerep ranks #44 out of 193 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Eurofins-Cerep has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Eurofins-Cerep's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins-Cerep ranks #44 out of 193 companies for PB Ratio. This places Eurofins-Cerep in the top 23% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.15. Eurofins-Cerep's value of 1.07 is 50.2% below this benchmark. Historically, Eurofins-Cerep's own PB Ratio has ranged from 0.78 to 2.65 over the past decade. While the company's 10-year median is 1.49 vs. the industry median of 2.15, Eurofins-Cerep has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.15, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins-Cerep's current PB Ratio of 1.07 is 50.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Eurofins-Cerep and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins-Cerep's current PB Ratio is 1.07, which is 28% below median its own 10-year median of 1.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins-Cerep stock overvalued right now?
Eurofins-Cerep (XPAR:ALECR) has a current PB Ratio of 1.07. The stock's GF Value™ is €20,199.84, compared to a current price of €16,300.00 — trading 19.3% below its estimated fair value. The current PB Ratio is 1.07, which is 28% below median its 10-year median of 1.49 and 50.2% below the Medical Diagnostics & Research industry median of 2.15. Eurofins-Cerep's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Eurofins-Cerep (XPAR:ALECR), the current PB Ratio is 1.07 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins-Cerep (XPAR:ALECR) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins-Cerep stock appears to be undervalued.
The current stock price of €16,300.00 is trading 19.3% below its estimated GF Value™ of €20,199.84.
Key valuation signals for XPAR:ALECR:
PB Ratio: 1.07 (28% below median its 10-year median of 1.49)
GF Value™: €20,199.84 vs. price of €16,300.00 (19.3% below fair value)
Industry Position: 50.2% below the Medical Diagnostics & Research median (#44 of 193)
No single metric tells the full story. See the XPAR:ALECR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
28GF Score
Get the complete analysis for XPAR:ALECR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALECR has been successfully added to your 
